Thelansis

Myelodysplastic Syndromes (MDS) Market Outlook Thelansis’s “Myelodysplastic Syndromes (MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myelodysplastic Syndromes (MDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Myelodysplastic Syndromes (MDS) Overview Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematopoietic stem cell disorders characterised by ineffective haematopoiesis, peripheral blood cytopenias, dysplastic bone marrow morphology, and variable risk of transformation to acute myeloid leukaemia. Somatic mutations in splicing factor genes — SF3B1, SRSF2, U2AF1 — epigenetic regulators incl...

Myelodysplastic Syndromes (MDS) Market Outlook Thelansis’s “Myelodysplastic Syndromes (MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myelodysplastic Syndromes (MDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest ...

Myelodysplastic Syndromes (MDS) Market Outlook Thelansis’s “Myelodysplastic Syndromes (MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myelodysplastic Syndromes (MDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

Myelodysplastic Syndromes (MDS) Market Outlook Thelansis’s “Myelodysplastic Syndromes (MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myelodysplastic Syndromes (MDS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Myelodysplastic Syndromes (MDS) Overview Myelodysplastic syndrome (MDS) comprises a group of myeloid hematological disorders distinguished by reduced blood cell counts, abnormalities in the bone marrow, and a significant risk of evolving into acute myeloid leukemia (AML). Clinical manifestations primarily result from low blood cell counts, predominantly anemia, leading to fatigue, shortness of breath, and poten...

 Myelodysplastic syndrome (MDS) comprises a group of myeloid hematological disorders distinguished by reduced blood cell counts, abnormalities in the bone marrow, and a significant risk of evolving into acute myeloid leukemia (AML). Clinical manifestations primarily result from low blood cell counts, predominantly anemia, leading to fatigue, shortness of breath, and potentially angina. Less frequently, MDS may manifest as thrombocytopenia, resulting in spontaneous bleeding or neutropenia, making individuals susceptible to bacterial or, in rarer cases, fungal infections. The underlying cause remains unknown in 80% of cases. In the remaining 20%, it may be attributed to acquired factors such as prior chemotherapy or radiation therapy, occupational exposure to benzene derivatives or ionizing radiation, or inherited factors, including gene mutations mainly involving DDX41, GATA2, RUNX, and telomerase genes, or DNA instability (notably seen in Fanconi anemia patients who are prone to de...

Myelodysplastic syndromes (MDS) are a group of myeloid malignancies that result in dysplastic and ineffective hematopoiesis and have a poor 5-year relative survival estimate. The only curative treatment option for MDS is stem cell transplantation following high-dose chemotherapy and total body irradiation, which, given the toxicity of the treatment regimen, is typically reserved for younger, healthier patients. MDS in older patients or those without a suitable bone marrow donor is generally limited to supportive care with transfusions, hematopoietic growth factors, or chemotherapy. The incidence of MDS patients identified as eligible for 2nd -line therapy was 3/100,000. Approximately 9,500 people per year in the United States may be candidates for 2nd -line therapy for MDS. The risk of MDS increases with advancing age; approximately 86% of patients with newly diagnosed MDS in the United States are 60 years old (median age, 76 years). Thelansis’s “Myelodys...